Developments Shuttle doses first patient in Phase 2 trial of Ropidoxuridine for glioblastoma Shuttle Pharmaceuticals (NASDAQ:SHPH) has announced the successful dosing of the first three patients in its Phase 2 clinical trial of Ropidoxuridine, aimed at treating glioblastoma. Ropidoxuridine, Shuttle’s lead... October 29, 2024